GLP-1 Allergic Reactions and Anaphylaxis: What the Labels and Cases Show

Yes, a true allergy to semaglutide or tirzepatide exists, and every label for Ozempic, Wegovy, Mounjaro and Zepbound carries a warning for anaphylaxis and angioedema. It is rare. In a US cohort of nearly 700,000 new users, anaphylaxis occurred at 3.6 per 10,000 person-years on semaglutide,^[5] and in Zepbound’s weight-loss trials 0.1% had a severe allergic reaction against none on placebo.^[4] Milder allergic reactions, mostly hives, rash and itching, are far more common, affecting a few percent of people in the tirzepatide trials. A serious reaction rules that drug out for good. Whether a different GLP‑1 is safe afterward has never been studied in a trial; the labels say only to use caution.

What each label says about allergy

All four labels make the same two moves. Anyone who has had a severe reaction to the medicine itself, or to one of its inactive ingredients, should not be given it again: that is a formal contraindication. And they put anaphylaxis and angioedema in the warnings section, with the instruction to stop the drug and get treatment.^[1][3] The Ozempic version reads:

Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with OZEMPIC. If hypersensitivity reactions occur, discontinue use of OZEMPIC; treat promptly per standard of care, and monitor until signs and symptoms resolve.

— Ozempic prescribing information, section 5.8

Where the labels differ is in how much trial data they print. Ozempic gives no trial figure for allergic reactions; it lists anaphylaxis, angioedema, rash and urticaria among reports collected after approval.^[1] The tirzepatide labels give the most detail.

Two things in that table matter. Zepbound’s own label says the bulk of these reactions involved the skin, mainly rash or itch,^[4] so the 2% to 5% figures are not a measure of anaphylaxis. And the excess on Zepbound was concentrated in reactions that began within a day of an injection, the timing most typical of a drug allergy.^[4] Widespread rash and itching that is not an emergency is covered in GLP-1 skin sensitivity, rash and itching.

How rare anaphylaxis actually is

Trials are too small to count a reaction this rare, so the best numbers come from insurance records. A 2024 cohort drew on three large US claims databases and followed 696,089 adults with type 2 diabetes who started a GLP‑1 between 2017 and 2021, using a validated algorithm to find anaphylaxis.^[5]

Put plainly: if 10,000 people took semaglutide for a year, about four would be expected to have anaphylaxis. The authors concluded that anaphylaxis is rare with this drug class.^[5] The study was funded by and co-authored with employees of Sanofi, which makes lixisenatide, the drug it was set up to examine. Tirzepatide was not included.

An earlier multinational cohort asked whether the rate is higher than on other diabetes drugs.^[6] Against DPP‑4 inhibitors, GLP‑1 users had 36.9 anaphylaxis events per 100,000 person-years against 32.1, a difference that was not statistically clear (hazard ratio 1.15, 95% CI 0.94 to 1.42). Against SGLT‑2 inhibitors the gap was firmer: 40.7 against 29.4 (hazard ratio 1.38, 95% CI 1.02 to 1.87). The authors called it a modest increase. Both cohorts were people with diabetes on older drugs and doses, not people using semaglutide or tirzepatide for weight loss.

FDA’s adverse-event database adds volume, not rates. As of its July 2026 update, it held 105 reports listing semaglutide with “anaphylactic reaction” and 270 listing tirzepatide, plus 85 and 152 listing angioedema.^[19] These are reports in which the drug was named, not cases the drug was shown to cause, and the counts cannot be compared between drugs because use and reporting habits differ. A European disproportionality study of the same kind found hypersensitivity in 0.58% of semaglutide reports and 0.73% of liraglutide reports; the authors stressed that reporting biases limit what such signals mean.^[18]

Allergic to one GLP-1, allergic to all of them?

Nobody knows, and the labels say so. Each one tells prescribers to use caution in someone with a history of anaphylaxis or angioedema on another GLP‑1, because it is unknown whether that person is predisposed to react again.^[2][3] The labels do not forbid trying another drug, and they do not endorse it.

Semaglutide is a modified version of human GLP‑1, while tirzepatide is built on the sequence of a different hormone, GIP.^[1][4] Being different molecules means cross-reaction cannot be assumed, but it cannot be ruled out either. That is chemistry, not evidence about any one patient. What exists is a handful of case reports pointing both directions:

• Tirzepatide reaction, semaglutide tolerated. A 25-year-old developed lip swelling and hives over four days after her first 10 mg dose, having tolerated the lower steps. Skin-prick testing to tirzepatide was negative but intradermal testing was positive. Intradermal testing to semaglutide was negative, a supervised 0.25 mg semaglutide dose was tolerated, and she continued on it without recurrence.^[7]
• Semaglutide tolerated, then a tirzepatide reaction. A 67-year-old who had previously used semaglutide developed severe itching and generalized hives after her first tirzepatide dose.^[10] Having taken one drug safely did not protect her on the other.
• Older drugs. Allergists have described patients who reacted to exenatide and lixisenatide but not to liraglutide,^[8] and a patient with confirmed anaphylaxis to an exenatide-type drug who later tolerated liraglutide.^[9]

A switch after a serious reaction is a decision for a prescriber, ideally with an allergist involved. How doses translate between drugs, which they mostly do not, is covered in switching between GLP-1 drugs.

Antibodies: common, and usually harmless

Many people form antibodies against these drugs. The labels report it under “immunogenicity”, and the numbers can alarm anyone who reads them cold.

Each label warns that the antibody rate depends heavily on how sensitive the test is, which is why Wegovy’s figure jumped when a newer assay was used.^[2] People with antibodies did report more allergic reactions, but the large majority of antibody-positive patients on every drug had none. Zepbound’s label states that no clinically significant effect of the antibodies on how the drug is absorbed or how well it works has been identified.^[4] The labels do not say these antibodies are the IgE type that drives anaphylaxis, and there is no routine blood test to check before starting.

The inactive ingredients

The contraindication covers the excipients as well as the drug, so the ingredient list is worth knowing. It depends on the device, not just the brand.^[1][2] The tirzepatide presentations follow the same pattern.^[3][4]

The preservatives (phenol, benzyl alcohol) appear only in the multi-dose devices. None of the four labels lists m-cresol or polyethylene glycol. No published case in our search attributed an allergic reaction to a GLP‑1 product’s excipient rather than the drug itself. The closest parallel is insulin, where allergists report that some reactions are to excipients such as metacresol, zinc or protamine, but many are to the insulin molecule.^[15] Someone with a documented allergy to phenol or benzyl alcohol has a concrete question to put to the prescriber: whether a single-dose presentation without them is an option.

Compounded vials: an ingredient list nobody has reviewed

Everything above describes FDA-approved products. A compounded semaglutide or tirzepatide vial has no FDA label, and FDA says plainly that compounded drugs reach patients without any agency check of their safety, quality or whether they work.^[20] The preservative, any added vitamin and even the salt form of the drug vary by pharmacy. What to look for on the vial is laid out in what is in a compounded GLP-1 vial. After a reaction to a compounded product, ask the pharmacy for the full ingredient list; it is the only way an allergist can tell what you reacted to.

Dosing mistakes complicate the picture. One 2026 case describes a 50-year-old woman whose lips, tongue and throat swelled four hours after her first injection of compounded semaglutide; she needed a breathing tube for four days. She later realized she had injected 2 mg, ten times the intended starting dose. She also had a past episode of angioedema on lisinopril, a blood-pressure drug.^[14] Accidental overdoses with compounded vials are covered in GLP-1 overdose: what happens.

Recognizing anaphylaxis, and what to do

The tirzepatide Medication Guide tells patients to stop the drug and get help at once for swelling of the face, lips, tongue or throat, trouble breathing or swallowing, severe rash or itching, fainting or dizziness, or a very fast heartbeat.^[4] In the published cases the reaction began within minutes to hours of an injection, sometimes the very first.^[12][14]

Two features make a GLP‑1 reaction harder to manage than a reaction to a pill taken once.

• Symptoms can come back. In a 2026 case, a 37-year-old treated with two doses of epinephrine after her first tirzepatide injection had hives, facial swelling and chest tightness return about an hour later with no further exposure.^[12] An earlier report described the same two-wave pattern, called a biphasic reaction, with tirzepatide.^[13] That is one reason emergency staff observe people after the first symptoms settle.
• The drug stays in the body. Half of an injected semaglutide dose is still in the body roughly seven days later, and half of a tirzepatide dose roughly five days later,^[1][4] so an injected dose cannot be removed. In the case of the 25-year-old above, the swelling and hives kept recurring for four days despite steroids and antihistamines.^[7]

The 2023 practice parameter from US allergy societies stresses training on when to use an epinephrine auto-injector and when to call 911, and names a blood tryptase level as important for confirming that a reaction was anaphylaxis.^[16] If a sample can be drawn during the emergency visit, it helps the allergist later.

After a reaction

1. Do not take the next dose until the prescriber has heard what happened. After a serious reaction, the label rules that drug out.
2. Write down the details. Which product and device, the dose, the lot number if you still have the pen or vial, the time from injection to symptoms, and what treatment you needed.
3. Ask for an allergist referral. After anaphylaxis, the WAO guidance advises seeing a specialist to work out the cause.^[17] Skin testing to tirzepatide has confirmed anaphylaxis in at least one published case,^[11] and intradermal testing plus a supervised dose identified a safe alternative in another.^[7]
4. Report it. FDA accepts reports through MedWatch,^[20] and each label lists the manufacturer’s reporting line.
5. Separate the allergy from the rest. A sore, itchy lump where you injected is usually local and does not by itself mean allergy, while widespread hives that come without swelling still need a call before the next dose. Other side effects and how long they last are covered in how long GLP-1 side effects last.

Desensitization, a supervised schedule of gradually increasing doses, has been reported for exenatide in two patients without another option.^[9] We found no published report of it for semaglutide or tirzepatide.